ClinicalTrials.gg
TerminatedNCT04802057Updated Sep 11, 2025

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

A Phase 1 interventional study of SAR445088 in Autoimmune Haemolytic Anaemia, sponsored by Bioverativ, a Sanofi company. Terminated at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Bioverativ, a Sanofi company (part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Anemia, Hemolytic, Autoimmune with a site in Germany — 3 open to participants now, 7 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · Germany.

Enrollment
16th of 17
9 · median 24
Started
2021
with 3 others
Phase 1
2 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
4 of 18
Bioverativ, a Sanofi company

Among the 18 studies in Anemia, Hemolytic, Autoimmune with a site in Germany, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2021, is one of 2 in phase 1, and was the 9th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

3 of the 18 studies in Anemia, Hemolytic, Autoimmune with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Anemia, Hemolytic, Autoimmune with a site in Germany, or all of them as a file.
02

Study summary

Primary Objective:

To assess the long-term safety and tolerability in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088

Secondary Objective:

To assess, in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088:

  • The long-term effect of SAR445088 on complement mediated hemolysis
  • The long-term pharmacodynamics (PD) effect of SAR445088 relating to complement inhibition
  • The long-term pharmacokinetic (PK) profile of SAR445088
  • The long-term immunogenicity of SAR445088
Read the detailed description

The screening period for this study is up to 6 weeks. The treatment period for this study will continue for 2 years after last participant entered Part 2 (either having switched from Part 1 or as a SAR445088-naïve participant), or until SAR445088 development is discontinued, whichever comes first.

03

Conditions studied

  • Autoimmune Haemolytic Anaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adult patients ≥18 years of age with CAD who were previously treated with SAR445088 and met criteria the below criteria for entry into Part 1:

    • met the eligibility criteria of a previous study evaluating SAR445088;
    • successfully enrolled and completed dosing in a previous study evaluating SAR445088;
    • successfully completed end of study procedures in a previous study evaluating SAR445088; and
    • per Investigator judgement, had a favorable benefit-to-risk profile after receiving SAR445088.
  • OR were never treated with SAR445088 before entering Part 2, and met the below criteria to establish CAD diagnosis:

    • chronic hemolysis;
    • polyspecific direct antiglobulin test (DAT) positive status;
    • monospecific DAT strongly positive for C3d;
    • cold agglutinin [CAg] titer ≥64 at 4°C;
    • IgG DAT ≤1+;
    • level ≤10 g/dL;
    • elevated not attributable to liver disease;
  • Documented vaccinations against encapsulated bacterial pathogens given within five years of enrollment and at least 14 days prior to dosing (vaccinations have to be initiated at least 14 days prior to dosing and completed before Week 5 of Part 2).
  • (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
  • Having given written prior to undertaking any study-related procedure.

Exclusion criteria

Exclusion Criteria:

  • Cold agglutinin syndrome secondary to infection, rheumatologic disease, or known high-grade hematologic , or known solid organ tumor.
  • infection within 1 month of enrollment.
  • Clinical diagnosis of systemic lupus erythematosus (SLE).
  • Treatment with anti-CD20 monotherapy within 3 months or anti-CD20 combination therapies within 6 months prior to screening.
  • Concurrent treatment with systemic agents targeting B- or T-cell function and/or cytotoxic agents within 3 months prior to screening. Concurrent treatment with other systemic immunosuppressants within 5.5 half-lives of the drug prior to screening.
  • Any specific complement system inhibitor other than SAR445088 (eg, eculizumab) within 3 months prior to screening.
  • Concurrent treatment with systemic other than a stable daily dose equivalent to ≤10 mg/day prednisone within 3 months prior to screening.
  • History of to SAR445088 or any of its components.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    SAR445088

    Repeat dose of SAR445088

    Drug: SAR445088

Interventions

  • Pharmaceutical form: solution for injection Route of administration: IV and SC (Part 1) IV (Part 2)

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAE)

    The number of participants experiencing TEAEs will be reported for the overall safety population.

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

Secondary outcomes

  1. Mean change from baseline in total bilirubin over time

    Assessment of total bilirubin

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

  2. Mean change from baseline in hemoglobin over time

    Assessment of hemoglobin

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

  3. Mean change from baseline in lactate dehydrogenase over time

    Assessment of lactate dehydrogenase

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

  4. Mean change from baseline in reticulocyte count over time

    Assessment of reticulocyte count

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

  5. Complement System Classical Pathway Levels as Measured by WIESLAB Assay

    Inhibition by SAR445088 of the complement system classical pathway measured by the WIESLAB assay.

    Time frame: Day 1 or Day 1-IV to Week 48-IV

  6. Complement System Alternative Pathway Levels as Measured by WIESLAB Assay

    Part 1: Effect of SAR445088 on the complement system alternative pathway measured by the WIESLAB assay.

    Time frame: Day 1 to Week 24

  7. Mean change in CH50 over time

    Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity. It will be assessed using complement assays.

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

  8. Total Complement Factor C4 Levels

    Total C4 Levels will be assessed in plasma using complement assays

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

  9. PK parameter: Cmax

    Maximum observed concentration (Cmax) of SAR445088 in plasma will be assessed

    Time frame: Day 1 or Day 1-IV to Week 48-IV

  10. PK Parameter: AUC

    Area under the plasma concentration versus time curve calculated using the trapezoidal method at steady state

    Time frame: Day 1 or Day 1-IV to Week 48-IV

  11. Number of participants with anti-SAR445088 antibodies

    The immunogenicity for SAR445088 will be assessed by summarizing the number of participants with anti-SAR445088 antibodies (ADA)

    Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years

07

Study locations

5 sites
  • Investigational Site Number : 2760001
    Essen, 45147, Germany
  • Investigational Site Number : 3800001
    Milan, Milano 20122, Italy
  • Investigational Site Number : 5280001
    Amsterdam, 1081 HV, Netherlands
  • Investigational Site Number : 5780001
    Bergen, 5021, Norway
  • Investigational Site Number : 8260001
    London, London, City of NW1 2PG, United Kingdom
08

References and documents

Publications

  • Chow T, Wardecki M, Storek M, Wong N. Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses. Clin Pharmacol Ther. 2025 Aug;118(2):449-458. doi: 10.1002/cpt.3692. Epub 2025 Apr 30. PubMed 40308078 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Mar 2025, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2021
First posted
Mar 17, 2021
StartActual
Mar 22, 2021
Primary completionActual
Mar 4, 2025
CompletionActual
Mar 4, 2025
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04802057
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Mar 22, 2021
Primary completion
Mar 4, 2025
Completion
Mar 4, 2025
Last update
Sep 11, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riliprubart

Start the discussion